醋酸环丙孕酮治疗良性前列腺增生症 - Suppr

Suppr

超能文献

Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate.

作者信息

Scott W W, Wade J C

出版信息

J Urol. 1969 Jan;101(1):81-5. doi: 10.1016/s0022-5347(17)62279-1.

DOI:10.1016/s0022-5347(17)62279-1

PMID:4178189

Abstract

摘要

相似文献

Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate.

J Urol. 1969 Jan;101(1):81-5. doi: 10.1016/s0022-5347(17)62279-1.

Evaluation of hydroxyprogesterone caproate in the treatment of benign prostatic hyperplasia.

South Med J. 1967 Nov;60(11):1174-6. doi: 10.1097/00007611-196711000-00006.

Effect of hydroxyprogesterone caproate on experimental benign prostatic obstruction in the mouse.

Isr J Med Sci. 1973 Nov-Dec;9(11):1559-64.

Therapy with progestational agents in advanced benign prostatic hypertrophy.

JAMA. 1969 Nov 24;210(8):1421-7.

[Clinical and cysto-sphincterometric results of progestogen therapy of prostatic adenoma].

Clin Ter. 1971 Jun 15;57(5):399-416.

[Determination of the size of the prostate by injection urethrocystography].

Ugeskr Laeger. 1976 Jun 14;138(25):1515-8.

Effect of progestational agents on gonadal and adrenal cortical function in patients with benign prostatic hypertrophy and carcinoma of the prostate.

J Clin Endocrinol Metab. 1967 Apr;27(4):556-60. doi: 10.1210/jcem-27-4-556.

The effect of antiestrogen, antiandrogen, and the prolactin inhibitor 2 bromo-alpha-ergocriptine on the stromal tissue of human benign prostatic hyperplasia. Correlation of stereological data and plasma hormones.

Invest Urol. 1981 Jan;18(4):308-12.

[Pathogenesis and norsteroid treatment of bladder neck adenoma (prostatic hypertrophy)].

Acta Chir Acad Sci Hung. 1973 Aug;14(3):209-22.

The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia.

N Engl J Med. 1987 Sep 3;317(10):599-604. doi: 10.1056/NEJM198709033171004.

引用本文的文献

Pharmacological Treatment of Perianal Gland Tumors in Male Dogs.

Animals (Basel). 2023 Jan 28;13(3):463. doi: 10.3390/ani13030463.

Temporal changes in physiological and molecular markers in various brain regions following transient global ischemia in rats.

Mol Biol Rep. 2019 Dec;46(6):6215-6230. doi: 10.1007/s11033-019-05060-7. Epub 2019 Sep 7.

Benign prostatic hyperplasia: An overview of existing treatment.

Indian J Pharmacol. 2011 Feb;43(1):6-12. doi: 10.4103/0253-7613.75657.

A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia.

Drug Saf. 1998 Mar;18(3):161-70. doi: 10.2165/00002018-199818030-00002.

Pharmacotherapy for benign prostatic hyperplasia.

West J Med. 1994 Nov;161(5):495-506.

Candicidin treatment of prostatism: a prospective double-blind placebo-controlled study.

Urol Res. 1983;11(1):7-10. doi: 10.1007/BF00272701.

Gestagens in the management of prostatic carcinoma.

Int Urol Nephrol. 1984;16(4):327-35. doi: 10.1007/BF02081869.

Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man.

J Clin Invest. 1970 Sep;49(9):1737-45. doi: 10.1172/JCI106391.

Benign prostatic hyperplasia: the best treatment.

BMJ. 1989 Jul 22;299(6693):215-6. doi: 10.1136/bmj.299.6693.215.

Antiandrogenic treatment of benign prostatic hyperplasia: a placebo controlled trial.

Urol Res. 1989;17(1):29-33. doi: 10.1007/BF00261046.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验